UNSPSC 51262902: Flusoxolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1GPL60IRCI. European Medicines Agency schedules Flusoxolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07753MIG. Flusoxolol generally arises in the molecular formula C22H30FNO4.

UNSPSC 51262902 Flusoxolol, a Commodity code, nominally refers to a specific pharmaceutical ingredient, but recent state and local procurement activity under this code shows little relevance to the code's technical definition. State and local governments are not soliciting flusoxolol itself; instead, the two recent opportunities tagged to this code involve naloxone (an opioid antagonist used in overdose reversal), safe drug deactivation systems, and direct-to-manufacturer pharmacy benefit program implementation—none of which align with flusoxolol's pharmaceutical profile. The mismatch suggests either a tagging error in the underlying procurement databases or that this code has drifted from its intended scope within state and local classification systems. Given the disconnect between the code name and actual procurement activity, this Commodity code presents minimal guidance for vendors in the pharmaceutical or pharmacy services space.

The two recent opportunities indicate activity in Florida and Texas through different issuing bodies and procurement mechanisms. Seminole County, Florida posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date and may reflect a data error in the source). The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026, to explore vendor capabilities for a direct-to-manufacturer prescription program aimed at improving pharmacy benefit administration outside traditional pharmacy benefit manager channels. Neither opportunity directly maps to flusoxolol procurement, and the absence of additional recent solicitations under this code suggests it is inactive or misclassified in current state and local procurement systems.